Table 1 Characteristics of the included COS development studies in prostate cancer (n = 11)
First Author [ref] | Year | Study type | Target population | Methods for consensus | Type of participants | Number of participants | Geographical origin |
|---|---|---|---|---|---|---|---|
Auvinen A [21] | 1996 | COS for clinical trials or clinical research | Men aged 56–67 eligible for screening | Meeting | Clinical experts; non-clinical research experts | 26 | Europe, Canada, United States |
Chen RC [22] | 2014 | COS patient reported outcomes | Adult patients (19+) with localized and advanced cancer | Systematic literature review; meeting | Clinical experts; non-clinical research experts; public representatives | NA | NA |
Dawson NA [23] | 1998 | COS for clinical trials or clinical research | Patients with hormone-refractory prostate cancer | Survey | Clinical experts | 35 | Europe, Canada, United States |
Denis L [24] | 1997 | COS for clinical trials or clinical research | Especially patients with localized cancer | Meeting | Clinical experts; others | 6 | Europe, United States |
MacLennan S [25] | 2017 | COS for clinical trials or clinical research | Patients aged 45–75 with localized prostate cancer undergoing surgery, active surveillance, ablative therapy, hormonal therapy | Meeting; Delphi; focus group; systematic literature review | Clinical experts; public representatives | 105 patients + 47 clinical experts | Europe, United States |
Martin NE [26] | 2015 | COS for practice | Men with newly diagnosed localized (stages T1-T4) cancer treated with curative intent or followed-up with active surveillance | Delphi; teleconferences; survey | Clinical experts; non-clinical research experts; public representatives | NA | NA |
Middleton RG [27] | 1995 | COS for clinical trials or clinical research | Patients with stage T2(B) prostate cancer undergoing radical prostectomy, radiation therapy, or surveillance | Literature review | NA | NA | United States |
Morgans A [28] | 2015 | COS for practice | Metastatic and recurrent patients ineligible for further curative therapy | Delphi; literature review; teleconferences | Clinical experts; non-clinical research experts; public representatives | 25 | Europe, Australia, Canada, United States |
Schellhammer P [29] | 1997 | COS for clinical trials or clinical research | Patients with localized cancer | Literature review; conference | Clinical experts; others | NA | Europe, Canada, United States |
van den Bos W [30] | 2014 | COS for clinical trials or clinical research | Patients with localized cancer and candidates for focal therapy | Delphi; meeting; literature review | Clinical experts | 48 | North America, Europe and Asia |
van den Bos W [31] | 2015 | COS for clinical trials or clinical research | Patients with localized recurrent disease after radiation therapy | Delphi; meeting; literature review | Clinical experts | 55 | NA |